

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
ON/4-32557A
APPLICATION NO.
10/520,359
APPLICANT
BREITENSTEIN ET AL.
FILING DATE
SEPTEMBER 12, 2005Group
4614
1624

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
DR	AA	5,516,775	5/14/96	Zimmermann et al.	-----	-----	
DR	AB	2006/0014742	1/19/06	Asaki et al.	-----	-----	
DR	AC	5,521,184	5/28/96	Zimmermann	-----	-----	
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
DR	AM	02/46170	6/13/02	WO	-----	-----	<input type="checkbox"/>	<input type="checkbox"/>
DR	AN	02/46171	6/13/02	WO	-----	-----	<input type="checkbox"/>	<input type="checkbox"/>
DR	AO	0 588 762	3/23/94	EP (English equivalent is US 5,516,775)	-----	-----	<input type="checkbox"/>	<input type="checkbox"/>
DR	AP	95/09853	4/13/95	WO	-----	-----	<input type="checkbox"/>	<input type="checkbox"/>
DR	AQ	2004/002963	1/8/04	WO (English equivalent is US 2006/0014742)	-----	-----	<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)


DR	AR	Zimmermann et al., "Potent and Selective Inhibitors of the ABL-Kinase: Phenylamino-Pyrimidine (PAP) Derivatives," Bioorganic & Medical Chemistry Letters, Vol. 7, No. 2, pp. 187-192 (1997)
DR	AS	Zimmermann et al., "Phenylamino-Pyrimidine (PAP) - Derivatives: A New Class of Potent and Highly Selective PDGF-Receptor Autophosphorylation Inhibitors," Bioorganic & Medicinal Chemistry Letters, Vol. 6, No. 11, pp. 1221-1226 (1996)
DR	AT	Paul et al., "Preparation of Substituted N-Phenyl-4-aryl-2-pyrimidinamines as Mediator Release Inhibitors," J. Med. Chem., Vol. 36, pp. 2716-2725 (1993)

EXAMINER /Deepak Rao/ DATE CONSIDERED 09/28/2006

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
ON/4-32557A
APPLICATION NO.
10/520,359
APPLICANT
BREITENSTEIN ET AL.
FILING DATE
SEPTEMBER 12, 2005Group
4644
1624

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	BA						
	BB						
	BC						
	BD						
	BE						
	BF						
	BG						
	BH						
	BI						
	BJ						
	BK						
	BL						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION YES NO	
DR	BM	JP 6-184116	7/5/94	JP (English equivalent is US 5,516,775)	-----	-----	<input type="checkbox"/>	<input type="checkbox"/>
	BN						<input type="checkbox"/>	<input type="checkbox"/>
	BO						<input type="checkbox"/>	<input type="checkbox"/>
	BP						<input type="checkbox"/>	<input type="checkbox"/>
	BQ						<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

DR	BR	Bhat et al., "Interactions of CBL with BCR-ABL and CRKL in BCR-ABL transformed Myeloid Cells," The Journal of Biological Chemistry, Vol. 272, No. 26, Issue of June 27, pp. 16170-16175 (1997)
DR	BS	Shibuya et al., "Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (<i>flt</i>) closely related to the <i>fms</i> family," Oncogene, Vol. 5, pp. 519-524 (1990)
	BT	

EXAMINER /Deepak Rao/

DATE CONSIDERED 09/28/2006

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.